As previously mentioned, inhibition of LSD1 regulates the expression of immune checkpoint molecules in immune cells as well as tumor cells, suggesting that LSD1 inhibitors show promising potential as a combinatory treatment in ICB therapy. The gene discussed is KDM1A; the disease is neoplasm.